Population pharmacokinetics and individualized dosing of vancomycin for critically ill patients receiving continuous renal replacement therapy: the role of residual diuresis
Frontiers in Pharmacology · 29.12.2023 · 14
DOI: 10.3389/fphar.2023.1298397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.12.2023. Verfasst von Zhenwei Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Vancomycin dosing is difficult in critically ill patients receiving continuous renal replacement therapy (CRRT). Previous population pharmacokinetic (PopPK) models seldom consider the effect of residual diuresis, a significant factor of elimination, and thus have poor external utility. This study aimed to build a PopPK model of vancomycin that incorporates daily urine volume to better describe the elimination of vancomycin in these patients.
Methods
We performed a multicenter retrospective study that included critically ill patients who received intermittent intravenous vancomycin and CRRT. The PopPK model was developed using the NONMEM program. Goodness-of-fit plots and bootstrap analysis were employed to evaluate the final model. Monte Carlo simulation was performed to explore the optimal dosage regimen with a target area under the curve of ≥400 mg/L h and 400–600 mg/L h.
Results
Overall, 113 observations available from 71 patients were included in the PopPK model. The pharmacokinetics could be well illustrated by a one-compartment model with first-order elimination, with the 24-h urine volume as a significant covariate of clearance. The final typical clearance was 1.05 L/h, and the mean volume of distribution was 69.0 L. For patients with anuria or oliguria, a maintenance dosage regimen of 750 mg q12h is recommended.
Conclusion
Vancomycin pharmacokinetics in critically ill patients receiving CRRT were well described by the developed PopPK model, which incorporates 24-h urine volume as a covariate. This study will help to better understand vancomycin elimination and benefit precision dosing in these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Research Center for Clinical Pharmacy, Zhejiang University, Hangzhou, China.
- The 903rd Hospital of PLA Joint Logistic Support Force, Hangzhou, China.
- Zhejiang Zhoushan Hospital, Zhoushan, China.
- College of Pharmaceutical Science, Zhejiang University, Hangzhou, China.
- The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zitieren
APA
Yu, Z., Liu, J., Yu, H., Zhou, L., Zhu, J., Liang, G., Yang, Y., Zheng, Y., Han, Y., Xu, J., Han, G., Yu, L., & Zhao, Y. (2023). Population pharmacokinetics and individualized dosing of vancomycin for critically ill patients receiving continuous renal replacement therapy: the role of residual diuresis. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1298397
Vancouver
Yu Z, Liu J, Yu H, Zhou L, Zhu J, Liang G, et al. Population pharmacokinetics and individualized dosing of vancomycin for critically ill patients receiving continuous renal replacement therapy: the role of residual diuresis. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1298397
BibTeX
@article{Yu2023,
author = {Yu, Zhenwei and Liu, Jieqiong and Yu, Haitao and Zhou, Ling and Zhu, Jianping and Liang, Gang and Yang, Yi and Zheng, Ying and Han, Yun and Xu, Junjun and Han, Gang and Yu, Lingyan and Zhao, Yuhua},
title = {Population pharmacokinetics and individualized dosing of vancomycin for critically ill patients receiving continuous renal replacement therapy: the role of residual diuresis},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1298397}
}
EUVIMED